Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
| ▸ | PNLIP | P16233 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794735 | 0.92 | GAA (0.51) | POLBGAASMOLMNAALDH1A1 | |
| SCHEMBL6801791 | 0.91 | NPC1 (0.46) | POLBGAASMOLMNAHTT | |
| SCHEMBL6792911 | 0.91 | SMO (0.47) | POLBGAASMOLMNAHTT | |
| SCHEMBL6795007 | 0.91 | SMO (0.48) | POLBGAASMOLMNAHTT | |
| SCHEMBL6793251 | 0.90 | SMO (0.42) | POLBGAASMOLMNAHTT | |
| SCHEMBL6793636 | 0.90 | SMO (0.42) | POLBGAASMOLMNAHTT | |
| SCHEMBL6799630 | 0.90 | SMO (0.42) | POLBGAASMOLMNAHTT | |
| SCHEMBL6791610 | 0.90 | SMO (0.42) | POLBGAASMOLMNAHTT | |
| SCHEMBL6795016 | 0.90 | POLB (0.42) | POLBGAASMOLMNAHTT | |
| SCHEMBL6792868 | 0.90 | GAA (0.42) | POLBGAASMOLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | MTTP 363/4885POLB 1470/4885GAA 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.